Ciprofloxacin Ciprofloxacine hydrochlorid

An example for the application of this calculation is given in Table 5.4 which shows the results of a collaborative trial for the establishment of ciprofloxacin hydrochloride CRS 2. The uncertainty was calculated to be o.ii %. 

Mao ZW, Ma L, Gao CY, Shen JC. Preformed microcapsules for loading and sustained release of ciprofloxacin hydrochloride. J Controlled Release 2005 104 193-202. 

Antibacterials ciprofloxacin hydrochloride co-trimoxazole (sulfamethoxazole/ trimethoprim) doxycycline hyclate mentronidazole vancomycin hydrochloride... 

Ciprofloxacin hydrochloride and hydrocortisone otic suspension contains the synthetic broad spectrum antibacterial agent, ciprofloxacin hydrochloride, combined with the anti-inflammatory corticosteroid, hydrocortisone, in a preserved, nonsterile suspension for otic use. Each milliliter contains ciprofloxacin hydrochloride (equivalent to 2 mg... 

Antibacterial Ciprofloxacin hydrochloride Ciloxan White petrolatum, propylene glycol, emulsifying wax... 

The commercially available injection for intravenous infusion that contains 2 mg/mL in 5% dextrose is provided in a plastic container fabricated from a specially formulated polyvinyl chloride (PVC). Tammilehto et al. used thin-layer chromatography to study the degradation of ciprofloxacin hydrochloride solutions after these were irradiated by a high pressure mercury lamp [6]. 

Calculate the content of Ci7Hi8FN303 in the tested tablets using the declared content of Ci7Hi9C1FN303 in ciprofloxacin hydrochloride... 

The assay of an IV formulation is performed using a liquid chromatographic method, which requires the following solutions. For solution (1), dilute a quantity of the intravenous infusion with sufficient mobile phase to produce a solution containing the equivalent of 0.05% w/v of ciprofloxacin. Solution (2) contains 0.058% w/v of ciprofloxacin hydrochloride EPCRS in mobile phase. Solution (3) contains 0.025% w/v of ciprofloxacin impurity C EPCRS (ethylenediamine compound) in solution (2). For solution (4), dilute 1 volume of solution (3) to 100 volumes with the mobile phase. The chromatographic procedure may be carried out using a stainless steel column (12.5 cm x 4 mm) packed with stationary phase C (5 mm) (Nucleosil C18 is suitable). The mobile phase is eluted at a flow rate of 1.5 mL/min, and consists of a mixture of 13 volumes of acetonitrile and 87 volumes of a 0.245% w/v solution of orthophosphoric acid (the pH of which has been adjusted to 3.0 with triethylamine). Analytes are detected on the basis of their UV absorption at 278 nm. The assay is not valid unless in the chromatogram obtained with solution (3), the resolution factor between the peaks due to ciprofloxacin and the ciprofloxacin impurity C is at least 1.5. 

Calculate the content of Ci7Hi8FN303 in the intravenous infusion formulation using the declared content of C17H19CIFN3O3 in ciprofloxacin hydrochloride EPCRS. Each milligram of Ci7H19ClFN303 is equivalent to 0.9010 mg of Ci7HigFN303. The ciprofloxacin content should be 95.0-105.0% of the label claim. 

Ciprofloxacin hydrochloride, in pharmaceutical raw material and capsules, has been analyzed by oscillopolarography [21]. A sample that was mixed with 2 mL of 0.5 M KH2P04/K0H buffer (pH 6.9), and diluted with water, yielded a reductive peak potential at —1.51 V vs. SCE. The calibration graph was linear from 0.1 to 20 pM, with an average recovery of 101.1% and a RSD of 1.14%. 

Mixtures of antibacterial agents (including ciprofloxacin hydrochloride) together with p-aminophenol (internal standard) in 0.1 M HC1 were... 

A mixture of four fluoroquinolones (including ciprofloxacin hydrochloride) was determined by high performance capillary electrophoresis using caffeine as an internal standard [58], A portion of the solution was... 

Nijhawan and Agarwal [140] investigated inclusion complexes of ciprofloxacin hydrochloride and hydroxy-propyl-P-cyclodextrin and found that the complexes exhibited better stability, biological activity, and ocular tolerance than the uncom-plexed drug in solution. 

Charoo, N. A., Kohli, K., Ali, A., and Anwer, A. (2003), Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations In vitro and in vivo studies, Drug Dev. Ind. Pharm., 29(2), 215-221. 

Vrabec TR, Sergott RC, Jaeger EA, Savino PJ, Bosley TM. Reversible visual loss in a patient receiving high-dose ciprofloxacin hydrochloride (Cipro). Ophthalmology 1990 97(6) 707-10. 

Balasubramaniam J, Pandit JK. Ion-activated in situ gelling systems for sustained release ophthalmic delivery of ciprofloxacin hydrochloride. Drug Delivery 2003 10(3) 185-191. 

The ciprofloxacin hydrochloride ophthalmic ointment consists of synthetic, sterile, multiple-dose, antimicrobials for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial that is active against a broad spectrum of gram-positive and gram-negative ocular pathogens. It is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-(l-piperazinyl)-3-quinoline-carboxylic acid. It is a faint to light-yellow... 

---